statistiche ricercatore

Continente	#
NA - Nord America	537
AS - Asia	243
EU - Europa	221
SA - Sud America	46
AF - Africa	29
Continente sconosciuto - Info sul continente non disponibili	22
OC - Oceania	1
Totale	1.099

Nazione	#
US - Stati Uniti d'America	516
SG - Singapore	75
IT - Italia	62
VN - Vietnam	58
CN - Cina	55
RU - Federazione Russa	40
BR - Brasile	39
DE - Germania	35
HK - Hong Kong	21
CI - Costa d'Avorio	18
FI - Finlandia	14
FR - Francia	14
CA - Canada	13
GB - Regno Unito	11
IE - Irlanda	9
IN - India	8
SE - Svezia	8
IQ - Iraq	5
JP - Giappone	5
NL - Olanda	5
AT - Austria	4
MA - Marocco	4
PL - Polonia	4
UA - Ucraina	4
AR - Argentina	3
BD - Bangladesh	3
CZ - Repubblica Ceca	3
EG - Egitto	3
BO - Bolivia	2
CH - Svizzera	2
EC - Ecuador	2
ID - Indonesia	2
LT - Lituania	2
OM - Oman	2
PH - Filippine	2
AE - Emirati Arabi Uniti	1
AU - Australia	1
BA - Bosnia-Erzegovina	1
CR - Costa Rica	1
CW - ???statistics.table.value.countryCode.CW???	1
EU - Europa	1
GE - Georgia	1
GR - Grecia	1
GT - Guatemala	1
HN - Honduras	1
JM - Giamaica	1
JO - Giordania	1
KE - Kenya	1
KR - Corea	1
MX - Messico	1
NG - Nigeria	1
NO - Norvegia	1
PK - Pakistan	1
PR - Porto Rico	1
SC - Seychelles	1
SI - Slovenia	1
SV - El Salvador	1
TN - Tunisia	1
TR - Turchia	1
TT - Trinidad e Tobago	1
UZ - Uzbekistan	1
Totale	1.079

Nome	#
85P NSCLC-Pro ClustAI: A machine learning model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors	202
The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab	169
NSCLC-Pro ClustAI: A Machine Learning Model to prognostically stratify patients with advanced NSCLC treated with immune checkpoint inhibitors	150
Old but gold: the role of drug combinations in improving response to immune check-point inhibitors in thoracic malignancies beyond NSCLC	149
SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry	133
Current Evidence and Future Perspectives about the Role of PARP Inhibitors in the Treatment of Thoracic Cancers	112
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study	100
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study	84
Totale	1.099

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	22	0	0	0	0	1	3	1	1	5	1	3	7
2022/2023	74	5	8	4	4	0	29	0	4	13	1	5	1
2023/2024	68	4	0	0	0	2	6	0	0	0	6	13	37
2024/2025	227	31	18	20	4	9	8	20	7	37	14	20	39
2025/2026	581	58	55	61	61	52	37	98	43	36	47	23	10
2026/2027	116	22	13	24	57	0	0	0	0	0	0	0	0
Totale													1.099